In June 2023, Premier Integrated Labs, formerly known as Pantai Premier Pathology, celebrated a momentous occasion with its official launch, marking a significant milestone. We take great pride in being the quadruple-crowned clinical laboratory in Malaysia, having attained the distinguished accreditations of the College of American Pathology (CAP), MS ISO 15189, Malaysian Society for Quality in Health (MSQH) and Joint Commission International (JCI).

MoU between Premier Integrated Labs, Genomax Technologies, and Veracyte

  HomePremier Integrated Labs  |  Newsroom  |  MoU between Premier Integrated Labs, Genomax Technologies, and Veracyte

Premier Integrated Labs, Genomax Technologies, and Veracyte collaborate to transform breast cancer care in Malaysia through a Memorandum of Understanding signing

The signing of the Memorandum of Understanding (MoU) between Premier Integrated Labs, Genomax Technologies, and Veracyte marks a significant milestone in advancing breast cancer care in Malaysia. The MoU was signed by Mr. Sayyidi Hamzi, Senior Manager of Premier Integrated Labs, Mr. Wong Lin Sheng, Managing Director of Genomax Technologies and Dr. Bertrand Farnault, Commercial Director of IVD at Veracyte. This collaboration introduces the Prosigna® Breast Cancer Assay (PAM50), making Premier Integrated Labs the sole local service provider of this cutting-edge diagnostic tool in Southeast Asia. We are driven by the belief that early, precise diagnosis is essential to improving patient outcomes.

Through this partnership, we are equipping healthcare providers with the latest genomic insights, empowering them to offer personalized treatment strategies to breast cancer patients. Together, we are transforming breast cancer care and helping patients make informed decisions about their treatment options.
Older post
Newer post